Tai Sandi See - 07 Jan 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role: Chief Development Officer
Signature: /s/ Youjin Choi, Attorney-in-Fact
Issuer symbol: LXEO
Transactions as of: 07 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 10 Jan 2025, 16:55:07 UTC
Previous filing: 06 Feb 2024
Next filing: 21 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LXEO	Common Stock	Award	$0	+38,750	+233%	$0.000000	55,375	07 Jan 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXEO	Stock Option (right to buy)	Award	$0	+77,500		$0.000000	77,500	07 Jan 2025	Common Stock	77,500	$7.33	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2	The reported securities are RSUs.
F3	25% of the shares underlying the option vest and become exercisable on January 7, 2026, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.